← All trials
NCT05872867
Phase 1Interventional
Includes initial studies to determine the metabolism and pharmacologic actions of drugs in humans, the side effects associated with increasing doses, and to gain early evidence of effectiveness; may include healthy participants and/or patients.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Jan 22, 2024
- Primary completion
- Feb 22, 2026
- Completion date
- Feb 22, 2026
- First posted
- May 24, 2023
- Last posted
- Oct 30, 2023
- Enrollment
- 54
- Arms / groups
- 2 / —
- Source
- AACT · ctgov ingestion
Sponsors
- Wellmarker BioLead sponsor
- MerckCollaborator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.